We've found
					184,457 				
					clinical trials				
				
			
		
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	 Clinical Trial
	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Orthopedics / Podiatry, Other Clinical Trial
	Rib Fixation for Clinically Severe Rib Fractures From Trauma
		Status: Enrolling	
	
	
			Updated: 11/2/2015	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Orthopedics / Podiatry, Other Clinical Trial
	Rib Fixation for Clinically Severe Rib Fractures From Trauma
		Status: Enrolling	
	
	
			Updated: 11/2/2015	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Immunology / Infectious Diseases, Oncology Clinical Trial
	Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Immunology / Infectious Diseases, Oncology Clinical Trial
	Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
		Status: Enrolling,
							Phase
													 I			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
							
  	
	Oncology Clinical Trial
	Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	
	
			Updated: 12/31/1969	
	  
  
  
  
			Click here to add this to my saved trials
	    
	
  
						
				
			
We've found
					184,457 
				
					clinical trials
				
				
				
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	 Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Orthopedics / Podiatry, Other Clinical Trial
	
Updated: 11/2/2015
  
  
  Rib Fixation for Clinically Severe Rib Fractures From Trauma
		Status: Enrolling	
	Updated: 11/2/2015
Click here to add this to my saved trials
	    
		
	Orthopedics / Podiatry, Other Clinical Trial
	
Updated: 11/2/2015
  
  
  Rib Fixation for Clinically Severe Rib Fractures From Trauma
		Status: Enrolling	
	Updated: 11/2/2015
Click here to add this to my saved trials
	    
		
	Immunology / Infectious Diseases, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Immunology / Infectious Diseases, Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
		Status: Enrolling,
							Phase
													 I			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials
	    
		
	Oncology Clinical Trial
	
Updated: 12/31/1969
  
  
  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
		Status: Enrolling,
							Phase
													 II			
				
		
	Updated: 12/31/1969
Click here to add this to my saved trials